SEC Filing Summary: Healthcare Acquisition Corp. (10-Q)
Business Context and Reporting Period
Company: Healthcare Acquisition Corp. (Note: Input metadata referenced "Altimmune, Inc.", but the filing text identifies the registrant as Healthcare Acquisition Corp., a Delaware corporation).
Reporting Period: Quarterly period ended June 30, 2005. The company was incorporated on April 25, 2005, and is classified as a "blank check" company (Special Purpose Acquisition Company) in the development stage.
Objective: To acquire a currently unidentified operating business in the healthcare industry through a merger, capital stock exchange, or asset acquisition. As of June 30, 2005, the company had not yet commenced any operations.
Key Financial Metrics
| Metric | Value (Period to June 30, 2005) |
|---|---|
| Cash and Cash Equivalents | $5,760 |
| Total Assets | $201,986 |
| Deferred Offering Costs | $196,226 |
| Total Liabilities | $179,486 |
| Notes Payable (Stockholders) | $175,000 |
| Stockholders' Equity | $22,500 |
| Net Loss | $(2,500) |
| Shares Outstanding | 2,250,000 (Founding shares) |
Note: The company consummated its Initial Public Offering (IPO) on August 3, 2005, subsequent to the reporting period. Net proceeds from the IPO were approximately $69,450,000, with $67,928,000 held in a trust account.
Material Changes and Subsequent Events
- Formation to IPO: The filing covers the period from inception (April 25, 2005) to June 30, 2005. The primary activity was formation and preparation for the public offering.
- Subsequent IPO: On July 28, 2005, the registration statement became effective. The company sold 9,000,000 units at $8.00 per unit, with an additional 400,000 units sold via over-allotment on August 16, 2005.
- Stock Dividends: The Board authorized stock dividends on July 8 and July 22, 2005. Share counts in the financial statements have been retroactively restated to reflect these transactions.
- Debt Repayment: The $175,000 in notes payable to stockholders (officers) outstanding at June 30, 2005, were repaid from IPO proceeds. An additional $75,000 in notes was issued in July 2005 and also repaid upon IPO consummation.
Outlook, Risks, and Management Commentary
- Business Combination Timeline: The company must consummate a business combination within 18 months of the IPO (or 24 months if extended). Failure to do so results in mandatory liquidation.
- Target Criteria: The initial business combination must be with a target having a fair market value of at least 80% of the company's net asset value (excluding trust cash and deferred underwriting fees).
- Liquidity and Expenses: Management believes the $1,522,000 held outside the trust fund is sufficient to operate through July 31, 2007. Anticipated expenses include $180,000 in administrative fees to affiliates, $600,000 for due diligence, and $492,000 for working capital.
- Redemption Rights: Public stockholders may redeem their shares for a pro-rata portion of the trust fund if they vote against a business combination. Approximately 19.99% of the trust fund is classified as temporary equity subject to redemption.
- Risks: There is no assurance a business combination will be completed. Funds in the trust account may be subject to third-party claims, though officers have agreed to be personally liable to protect the trust. The company is not currently exposed to market risks regarding foreign exchange or commodities.
Investor Verification Checklist
- Company Identity: Verify that the filing pertains to "Healthcare Acquisition Corp." and not "Altimmune, Inc." as suggested in the metadata.
- Trust Fund Status: Confirm the current balance and interest accrual on the $67,928,000 held in the JP Morgan Chase NY Bank trust account.
- Affiliate Transactions: Review the ongoing $7,500 monthly fee arrangement with affiliates (Equity Dynamics, Inc. and The Lan Group) for office space and services.
- Underwriter Option: Note the purchase option granted to the underwriter for 225,000 units at $10/unit, valued at approximately $852,750, and its potential dilution impact.
- Liquidation Deadline: Monitor the 18-month deadline from the August 3, 2005 IPO date for the consummation of a business combination.